Latest | F'cast | |
---|---|---|
Div Yield | 2.0% | 0.0% |
Div Cover | 2.6 | 2.8 |
Op Mrgn | 18.5% | 31.2% |
ROCE | 60.7% |
Latest | F'cast | |
---|---|---|
P/E | 18.6 | 16.1 |
PEG | 1.4 | 1.6 |
Pr/Revenue | 4.4 | 2.9 |
Pr/Book | 5.8 |
Latest | F'cast | |
---|---|---|
Revenue | 18.0% | -19.7% |
PBT | 26.0% | 56.1% |
EPS | 13.1% | 9.8% |
DPS | 6.9% | -41.4% |
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | 26,617.00 | 3,916.00 | 244.00¢ | 39.8 | 0.3 | +137% | 280.00¢ | 2.9% |
31-Dec-21 | 37,417.00 | (265.00) | 8.00¢ | 1,436.6 | n/a | -97% | 287.00¢ | 2.5% |
31-Dec-22 | 44,351.00 | 2,501.00 | 212.00¢ | 70.1 | 0.0 | +2,550% | 290.00¢ | 2.0% |
31-Dec-23 | 45,811.00 | 6,899.00 | 726.00¢ | 19.3 | 0.1 | +242% | 290.00¢ | 2.1% |
31-Dec-24 | 54,073.00 | 8,691.00 | 821.00¢ | 16.9 | 1.3 | +13% | 310.00¢ | 2.2% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-25 | 57,525.60 | 17,965.54 | 670.43p | 17.2 | 1.8 | +10% | 240.58p | 0.0% |
31-Dec-26 | 61,095.84 | 20,440.47 | 758.83p | 15.2 | 1.2 | +13% | 253.03p | 0.0% |
31-Dec-27 | 64,592.77 | 22,450.27 | 838.65p | 13.7 | 1.3 | +10% | 264.06p | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
H1 and Q2 2025 results | 29-Jul-2025 | 07:00 | RNS |
Gefurulimab nanobody met Phase III endpoints | 24-Jul-2025 | 07:00 | RNS |
AstraZeneca plans to invest $50bn in the US | 22-Jul-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 11,498.00p |
Change Today | 340.00p |
% Change | 3.05 % |
52 Week High | 13,276.00 |
52 Week Low | 9,667.00 |
Volume | 4,691,503 |
Shares Issued | 1,550.67m |
Market Cap | £178,296m |
Beta | 0.01 |
RiskGrade | 123 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 10 |
Buy | 14 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 0 |
Total | 29 |
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 07-Aug-25 | 20-Feb-25 |
Paid | 08-Sep-25 | 24-Mar-25 |
Amount | 103.00¢ | 210.00¢ |
Time | Volume / Share Price |
17:45 | 5,686 @ 11,430.33p |
16:05 | 0 @ 11,458.00p |
16:12 | 0 @ 11,480.00p |
15:59 | 1 @ 11,464.00p |
16:24 | 0 @ 11,472.00p |
You are here: research